Ansøg om midler

Challenge Programme 2023

For the application round of 2023, the Challenge Programme is seeking to support outstanding research collaborations working within one of three selected themes. Up to DKK 360 million will be awarded for grants of DKK 30-60 million each.

Theme 1: RNA- and Oligonucleotide-based Therapeutics 

The specific challenge of this theme is to support the basic science that facilitate development of RNA- and Oligonucleotide-based therapeutics beyond treatment of rare diseases and vaccine purposes. Such research is required to develop novel therapeutics for common clinical conditions, primarily cardiometabolic diseases, that is efficiently targeting the relevant tissue, cell types and subcellular localisation. 

Theme 2: Prediction of Climate Change and Effect of Mitigating Solutions 

The specific challenge of this theme is to develop data-driven, next-generation climate models with the purpose of enabling robust predictions of climate change and prediction of the effect of mitigating solutions. The aim is to significantly progress our causal understanding of the fundamental mechanisms and consequences on a regional and/or global scale. 

Theme 3: Future Agri-Food Systems 

The specific challenge of this theme is to enable a transformation of agri-food systems that will secure sustainable and healthy foods for all. The programme is aimed at fundamental and strategic research spanning primary production to consumption, as well as financial structures required for this transition.

Research strictly focusing on single parts of the value chain, e.g., breeding, ingredients, or food processing technologies, will be considered too narrow. Production of biomass for feed, energy, or materials may be part of the research if it constitutes an integrated part of a circular food system. Behaviour and preferences related to food consumption, livestock commodities, and regulatory frameworks are not in focus.

For further information, please read our press release: Challenge Programme 2023 themes.